Satraplatin

Jump to: navigation, search
Satraplatin.png
Satraplatin-from-xtal-1995-Mercury-3D-balls.png
Satraplatin
Systematic (IUPAC) name
(OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum
Identifiers
CAS number 129580-63-8
ATC code L01XA04
PubChem 123974
Chemical data
Formula C10H22Cl2N2O4Pt 
Mol. mass 500.277 g/mol
Synonyms BMY 45594
BMS 182751
(OC-6-43)-bis(acetato)amminedichlorocyclohexylamine platinum(IV)
Pharmacokinetic data
Bioavailability ?
Metabolism ?
Half life ?
Excretion ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes Oral

WikiDoc Resources for Satraplatin

Articles

Most recent articles on Satraplatin

Most cited articles on Satraplatin

Review articles on Satraplatin

Articles on Satraplatin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Satraplatin

Images of Satraplatin

Photos of Satraplatin

Podcasts & MP3s on Satraplatin

Videos on Satraplatin

Evidence Based Medicine

Cochrane Collaboration on Satraplatin

Bandolier on Satraplatin

TRIP on Satraplatin

Clinical Trials

Ongoing Trials on Satraplatin at Clinical Trials.gov

Trial results on Satraplatin

Clinical Trials on Satraplatin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Satraplatin

NICE Guidance on Satraplatin

NHS PRODIGY Guidance

FDA on Satraplatin

CDC on Satraplatin

Books

Books on Satraplatin

News

Satraplatin in the news

Be alerted to news on Satraplatin

News trends on Satraplatin

Commentary

Blogs on Satraplatin

Definitions

Definitions of Satraplatin

Patient Resources / Community

Patient resources on Satraplatin

Discussion groups on Satraplatin

Patient Handouts on Satraplatin

Directions to Hospitals Treating Satraplatin

Risk calculators and risk factors for Satraplatin

Healthcare Provider Resources

Symptoms of Satraplatin

Causes & Risk Factors for Satraplatin

Diagnostic studies for Satraplatin

Treatment of Satraplatin

Continuing Medical Education (CME)

CME Programs on Satraplatin

International

Satraplatin en Espanol

Satraplatin en Francais

Business

Satraplatin in the Marketplace

Patents on Satraplatin

Experimental / Informatics

List of terms related to Satraplatin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Satraplatin (INN, codenamed JM216) is a platinum-based antineoplastic agent that is under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. It has not yet received approval from the U.S. Food and Drug Administration.[1] First mentioned in the medical literature in 1993,[2] satraplatin is the first orally active platinum-based chemotherapeutic drug;[3] other available platinum analogues—cisplatin, carboplatin, and oxaliplatin—must be given intravenously.

It is made available in the United States jointly by Spectrum Pharmaceuticals and GPC Biotech under the name SPERA (SatraPlatin Expanded Rapid Access).

The drug has also been used in the treatment of lung and ovarian cancers. The proposed mode of action is that the compound binds to the DNA of cancer cells rendering them incapable of dividing.[4]

References

  1. Wheate, Nial J.; Walker, Shonagh; Craig, Gemma E.; Oun, Rabbab (2010). "The status of platinum anticancer drugs in the clinic and in clinical trials". Dalton Transactions. 39 (35): 8113–27. PMID 20593091. doi:10.1039/C0DT00292E. 
  2. Kelland LR, Abel G, McKeage MJ; et al. (1993). "Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug" (PDF). Cancer Res. 53 (11): 2581–6. PMID 8388318. 
  3. Choy H, Park C, Yao M (2008). "Current status and future prospects for satraplatin, an oral platinum analogue". Clin Cancer Res. 14 (6): 1633–8. PMID 18347164. doi:10.1158/1078-0432.CCR-07-2176. 
  4. Satraplatin — Spectrum Pharmaceuticals


Template:Antineoplastic-drug-stub


Linked-in.jpg